Preventing Illegal Laboratories and Protecting Public Health Act of 2026

Increased Accountability for Dangerous Materials: By requiring distributors to maintain an electronic logbook of sales, leases, loans, or transfers, the government can track who is receiving highly pathogenic agents and how they intend to use them (Section 2(c)).

Enhanced Safety Standards: The bill mandates the development of up-to-date national standards for the design, construction, operation, and maintenance of high-containment laboratories (Section 3(b)(2)).

Improved Communication and Support: The creation of a Public Health Biosafety and Biosecurity Team provides a single point of contact for State, local, Tribal, and territorial agencies to ask questions regarding laboratory biosafety and biosecurity (Section 3(d)(1)).

Strengthened Oversight: The requirement for a periodic strategic evaluation of high-containment laboratories allows the government to assess risks, capacity, and physical security measures (Section 3(b)).

Increased Regulatory Burden on Distributors: Covered distributors must comply with specific logbook requirements, which include collecting detailed information from purchasers such as their name, address, intended use, and signature (Section 2(c)(2)).

Strict Identification Requirements: To obtain highly pathogenic agents, purchasers must present specific forms of government-issued identification, which may create hurdles for some individuals or entities (Section 2(c)(3)(A)(i)).

Risk of Criminal Penalties: Purchasers are warned that providing false statements or misrepresentations in the required logbooks can lead to criminal penalties, including fines and imprisonment (Section 2(c)(4)).